NCT05081999Active, not recruitingPhase 4
De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease
De-Adoption βeta-Blockers in Patients With Stable Ischemic Heart Disease Without REduced LV Ejection Fraction, Ongoing Ischemia, or Arrhythmias: a pragmaTic randomizEd Trial With Blinded Endpoints
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
Patients with heart disease are often prescribed many medications and these patients may experience drug interactions or negative drug related side effects. With newer medications and treatments available, it is not well known whether older drugs, such as beta-blockers, are still an effective and safe option for treating heart disease. Some evidence suggests beta-blockers should be continued, whereas other evidence suggests beta-blockers might cause unnecessary harm. The study hopes to determine whether continuation or discontinuation of beta-blockers will affect long term cardiovascular outcomes. The study investigators will also examine how beta-blockers continuation or discontinuation affects several quality of life measures.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 59 (actual)
- First submitted
- 20 Sept 2021
- Start date
- Jan 2023
- Primary completion date
- Jan 2026
- Lead sponsor
- University of Alberta
- Diseases
- Coronary artery disease
- NCT number
- NCT05081999
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 59
- From Jan 2023 to the primary completion date, Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Myocardial infarction \<6 months prior to randomization
- Non-compliance with medical therapy
- Participation in another trial related to β-blockers or other anti-anginal drugs
Other illness
- Indication for β-blocker as determined by the treating physician (such as atrial or ventricular arrhythmias or ongoing angina not controlled by another agent)
- Uncontrolled hypertension or uncontrolled angina symptoms (per the Investigator's discretion)
Lab values
- Left Ventricular Ejection Fraction \< 40% or current hospitalization for heart failure
Other
- Life expectancy \<1 year
Who the study is looking for
- Age \>21 years
- Documented Coronary Artery Disease (CAD) defined as:
- Myocardial Infarction at least 6 months prior; or
- Stable ischemic heart disease (defined using one of the following tests suggestive of significant coronary artery disease):
- Positive exercise stress test ii. Positive Nuclear perfusion scan iii. Positive exercise or pharmacologic echocardiographic stress test iv. Positive magnetic resonance imaging coronary perfusion scan v. Coronary computed tomographic angiography Angiogram with stenosis ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing by CT (FFRCT); vi. Invasive coronary angiography with ≥ 70% (or left main coronary artery ≥ 50%) or significant function disease based or positive fractional flow reserve testing (FFR) or instant wave free ratio (IFR),
- Previous Percutaneous Coronary Intervention (PCI, at least 6 months prior if revascularization is performed for an MI); or
- Previous Coronary Artery Bypass Grafting (CABG, at least 6 months prior if revascularization is performed for an MI)
- Able and willing to provide informed consent
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Hospital Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.